Heartflow, Inc. - Common Stock (HTFL)

A key FDA-cleared analysis tool earned professional accolades for its utility.

Reinforces Role of AI-Powered Quantitative Coronary Plaque Assessment

Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England’s National Health Service

One family office fund just made Karman its biggest reported equity bet—here’s what long-term investors should take from the move.

A billionaire family office has made a big bet on a newly public AI-driven heart diagnostics company—here’s what long-term investors should take from the move.

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

MOUNTAIN VIEW, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in artificial intelligence (AI) technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference. The fireside chat will take place on Wednesday, December 3, 2025, at 12:30 p.m. PT / 3:30 p.m. ET.

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Stanford just bought into HeartFlow. Here is what caught Stanford’s eye and what investors need to know about HeartFlow’s early trajectory and long-term potential.

Heartflow Q3 2025 earnings show strong revenue growth, beating estimates, and confident full-year guidance.

Initiates Full Year 2025 Revenue Guidance of $173.0 Million to $173.5 Million

Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events

Data to highlight the precision of AI-powered Heartflow Plaque Staging framework in predicting long-term cardiovascular outcomes

MOUNTAIN VIEW, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will release financial results for the third quarter of 2025 after market close on Wednesday, November 12, 2025. Management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on November 12, 2025.

PLAN CALCIUM study to be presented at TCT 2025 conference highlights how AI-powered plaque analysis can inform lesion preparation and calcium modification planning